AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding 

Rhea-AI Summary

AEON Biopharma (NYSE American: AEON) priced an upsized underwritten public offering for expected gross proceeds of approximately $13.75 million, with potential total proceeds of up to about $43.3 million if all accompanying milestone warrants are exercised in cash.

The offering comprises 42,688,606 shares of common stock (or pre-funded warrants) at a combined public offering price of $0.3221 per share and two milestone warrants (or $0.3220 per pre-funded warrant package). Each package includes one two-year milestone warrant with a $0.3221 exercise price and one five-year milestone warrant with a $0.3704 exercise price, all immediately exercisable. AEON granted a 30-day over-allotment option for up to 6,403,290 additional shares and/or milestone warrants. Closing is expected on or about July 15, 2026, subject to customary conditions, and proceeds are intended for working capital and comparative analytical testing of ABP-450 to support its biosimilarity to BOTOX.

Positive

• $13.75 million expected gross proceeds from underwritten public offering
• Milestone warrants could add up to $29.6 million in cash proceeds
• Offering package covers 42.7 million shares or pre-funded warrants
• Use of proceeds includes ABP-450 biosimilarity testing to BOTOX

Negative

• Issuance of 42.7 million shares may significantly dilute existing shareholders
• Over-allotment option adds up to 6.4 million additional shares and warrants
• Two- and five-year milestone warrants create potential future equity overhang

News Market Reaction – AEON

+10.84% 562.3x vol

102 alerts

+10.84% Session close to close

-50.1% Trough in 6 hr 26 min

$12.71M Market Cap

562.3x Rel. Volume

In the Jul 14 session, AEON gained 10.84%, reflecting a significant positive market reaction. Argus tracked a trough of -50.1% from its starting point during tracking. Our momentum scanner triggered 102 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 562.3x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +10.8% in the session following this news. A strong upside reaction to this upsized...

Analysis

The stock surged +10.8% in the session following this news. A strong upside reaction to this upsized offering would contrast with AEON’s past offering-related moves, which averaged -40.31%. Investors might be focusing on added funding runway, though the active S-3 resale shelf still represents overhang and potential volatility.

Key Figures

Base offering size: $13.75 million Potential warrant proceeds: $29.6 million Maximum gross proceeds: $43.3 million +5 more

8 metrics

Base offering size $13.75 million Expected gross proceeds from underwritten public offering

Potential warrant proceeds $29.6 million Additional gross proceeds if all milestone warrants exercised in cash

Maximum gross proceeds $43.3 million Total gross proceeds combining base offering and full warrant exercise

Shares in offering 42,688,606 shares Common stock or pre-funded warrants sold with milestone warrants

Offering price $0.3221 per share Combined price per common share with two milestone warrants

Pre-funded unit price $0.3220 per pre-funded warrant Combined price per pre-funded warrant with two milestone warrants

Pre-funded exercise price $0.0001 per share Exercise price for each pre-funded warrant

Two-year warrant strike $0.3221 per share Exercise price of two-year milestone warrants

Previous Offering Reports

3 past events · Latest: Jan 07 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 07	Public offering close	Neutral	+5.2%	Closed $20.0M underwritten public offering of common units with warrants attached.
Jan 06	Offering pricing	Neutral	-63.1%	Priced $20.0M underwritten public offering of common and pre-funded units.
Jan 03	Offering launch	Neutral	-63.1%	Launched proposed public offering of common stock or pre-funded warrants plus warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For prior offering-related announcements, AEON has typically seen large negative price reactions, with an average move of -40.31%.

Key Terms

pre-funded warrant, milestone warrant, registration statement, form s-1, +1 more

5 terms

pre-funded warrant financial

"shares of common stock of the Company (or pre-funded warrants in lieu thereof)"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

milestone warrant financial

"accompanied by one two-year milestone warrant to purchase one share of common stock"

A milestone warrant is a special option to buy a company’s shares that only becomes usable if the company reaches a pre-set goal, such as regulatory approval, a sales target, or a clinical result. For investors this matters because it represents potential future dilution of shares and a contingent value transfer—similar to a coupon that only becomes valid once a store hits a sales target—so it affects how much existing shareholders own and the incentives driving management decisions.

registration statement regulatory

"A Registration Statement on Form S-1 (File No. 333-297327), as amended, relating"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

form s-1 regulatory

"A Registration Statement on Form S-1 (File No. 333-297327), as amended, relating"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

rule 462(b) regulatory

"a related registration statement was filed with the SEC on July 13, 2026 pursuant to Rule 462(b)"

Rule 462(b) is an SEC provision that lets an issuer add more securities of the same class to an already-effective registration statement by filing a short post-effective amendment that becomes effective on filing, so the additional securities are immediately registered without redoing the full approval process. For investors this matters because it lets companies and underwriters expand an offering quickly—like adding extra seats to a sold-out show—changing supply and potential dilution that can affect the stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering

IRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the pricing of its underwritten public offering to raise up to approximately $43.3 million in gross proceeds based on the approximately $13.75 million in expected gross proceeds from the offering and up to an additional $29.6 million in potential gross proceeds upon the cash exercise in full of the milestone warrants issued in the offering.

The offering consists of 42,688,606 shares of common stock of the Company (or pre-funded warrants in lieu thereof), with each share of common stock or pre-funded warrant accompanied by one two-year milestone warrant to purchase one share of common stock (or one pre-funded warrant in lieu thereof) and one five-year milestone warrant to purchase one share of common stock (or one pre-funded warrant in lieu thereof). The combined public offering price is $0.3221 per share of common stock (or $0.3220 per pre-funded warrant) and accompanying two-year milestone warrant and five-year milestone warrant. Each pre-funded warrant has an exercise price of $0.0001 per share of common stock. Each two-year milestone warrant has an exercise price of $0.3221 per share of common stock and each five-year milestone warrant has an exercise price of $0.3704 per share of common stock. Each pre-funded warrant, two-year milestone warrant and five-year milestone warrant will be immediately exercisable upon issuance. The pre-funded warrants may be exercised at any time until exercised in full. Each two-year milestone warrant will expire on the earlier of (i) the second anniversary of the date of issuance or (ii) 45 days following the Company's public announcement of the achievement of a specified regulatory milestone with respect to ABP-450. Each five-year milestone warrant will expire on the earlier of (i) the fifth anniversary of the date of issuance or (ii) 45 days following the Company's public announcement of the achievement of a specified clinical development milestone with respect to ABP-450.

The gross proceeds to the Company from this offering are expected to be approximately $13.75 million, before deducting underwriting discounts and commissions and other estimated offering expenses. If all of the two-year milestone warrants and all of the five-year milestone warrants sold in this offering were to be exercised in cash at their exercise price, we would receive additional gross proceeds of approximately $29.6 million, before deducting expenses and fees. The Company has also granted the representative a 30-day option to purchase up to an additional 6,403,290 shares of common stock (or pre-funded warrants in lieu thereof) and/or two-year milestone warrants to purchase up to an additional 6,403,290 shares of common stock (or pre-funded warrants in lieu thereof) and/or five-year milestone warrants to purchase up to an additional 6,403,290 shares of common stock (or pre-funded warrants in lieu thereof) solely to cover over-allotments, if any.

The offering is expected to close on or about July 15, 2026, subject to satisfaction or waiver of customary closing conditions.

The proceeds from this offering are expected to be used for working capital and general corporate purposes, including conducting comparative analytical testing on ABP-450 to support biosimilarity to BOTOX®.

Lake Street Capital Markets, LLC is acting as the sole bookrunner for this offering. Laidlaw & Company (UK) Ltd. is acting as lead manager for the offering.

A Registration Statement on Form S-1 (File No. 333-297327), as amended, relating to the securities was initially filed with the Securities and Exchange Commission (“SEC”) on July 8, 2026 and was declared effective on July 13, 2026, and a related registration statement was filed with the SEC on July 13, 2026 pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and became automatically effective upon filing (together, the “Registration Statement”). This offering is being made only by means of a preliminary prospectus forming a part of the Registration Statement and a final prospectus. The Registration Statement and the preliminary prospectus relating to the offering are available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus, when available, may be obtained from Lake Street Capital Markets, LLC, 121 S 8th St Suite 1000, Minneapolis, MN 55402, or e-mail at prospectus@lakestreetcm.com. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About AEON Biopharma
AEON Biopharma is a biopharmaceutical company advancing ABP-450 as a proposed biosimilar to BOTOX® for therapeutic indications. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau®. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories.

Forward Looking Statements
This press release contains statements that may be deemed "forward-looking statements" within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as "expect," "anticipate," "intend," "believe," "estimate," "will," and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to: expectations regarding the completion of the offering and the use of proceeds thereof; the Company's ability to achieve the milestones underlying the two-year and five-year milestone warrants; the Company's ability to advance ABP-450 through the Section 351(k) biosimilar pathway; the Company's ability to maintain compliance with the continued listing standards of the NYSE American; the Company's ability to complete its preclinical and clinical studies; and changes in local or national economic conditions. This list of risks, uncertainties, and other factors is not complete. Any or all forward-looking statements the Company makes may turn out to be wrong. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com

Source: AEON Biopharma

FAQ

What did AEON Biopharma (AEON) announce in its July 2026 public offering?

AEON Biopharma announced pricing of an underwritten public offering raising about $13.75 million, plus potential warrant proceeds. According to AEON, the deal includes common stock or pre-funded warrants bundled with two milestone warrants per unit, expanding its near-term and potential future funding.

How much money could AEON Biopharma (AEON) raise from the July 2026 offering and warrants?

AEON Biopharma expects about $13.75 million in gross proceeds, with up to $43.3 million possible including milestone warrants. According to AEON, full cash exercise of the two- and five-year milestone warrants could add roughly $29.6 million in additional gross proceeds before expenses.

What are the pricing terms for AEON Biopharma’s July 2026 stock and warrant offering?

The combined public offering price is $0.3221 per common share and warrant package, or $0.3220 per pre-funded unit. According to AEON, each unit includes a two-year warrant at $0.3221 and a five-year warrant at $0.3704, all immediately exercisable.

How many shares are included in AEON Biopharma’s (AEON) July 2026 equity offering?

The base deal includes 42,688,606 shares of common stock or pre-funded warrants, each with two milestone warrants. According to AEON, the underwriter also holds a 30-day over-allotment option for up to 6,403,290 additional shares and related milestone warrants.

When is AEON Biopharma’s July 2026 stock offering expected to close?

The offering is expected to close on or about July 15, 2026, subject to customary conditions. According to AEON, completion remains contingent on satisfaction or waiver of standard closing requirements for underwritten public offerings.

How will AEON Biopharma use the proceeds from its July 2026 public offering (AEON)?

AEON plans to use proceeds for working capital and general corporate purposes, including ABP-450 testing. According to AEON, funds will support comparative analytical studies to demonstrate ABP-450 biosimilarity to BOTOX for therapeutic use and potential full-label U.S. entry.

What are the milestone warrant terms in AEON Biopharma’s July 2026 offering?

Each unit includes a two-year and five-year milestone warrant, both immediately exercisable with different expiry triggers. According to AEON, expirations may accelerate to 45 days after specified regulatory or clinical milestones for ABP-450, depending on the particular warrant.